What JAVELIN PHARMACEUTICALS, INC's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Tulipano Stephen J | CFO and Secretary | Jul 02 | Disposition to Issuer · D | −12,500 | $2.20 | −$27.5K | 0 |
| Driscoll Martin J | Chief Executive Officer | Jul 02 | Disposition to Issuer · D | −59,524 | $2.20 | −$131K | 0 |
| Driscoll Martin J | Chief Executive Officer | Jul 02 | Disposition to Issuer · D | −179,529 | $2.20 | −$395K | 0 |
| Flanzraich Neil | Director | Jul 02 | Disposition to Issuer · D | −1,000,000 | $2.20 | −$2.2M | 0 |
| Carr Daniel B | President and CMO | Jul 02 | Disposition to Issuer · D | −59,524 | $2.20 | −$131K | 0 |
| Kiernan Peter D. Iii | Director | Jul 02 | Disposition to Issuer · D | −2,411,848 | $2.20 | −$5.31M | 0 |
| Tulipano Stephen J | CFO and Secretary | Jun 30 | Tender Offer · U | −10,115 | $2.20 | −$22.3K | 0 |
| Watson Douglas G | Director | Jun 30 | Tender Offer · U | −20,000 | $2.20 | −$44K | 0 |
| Mermelstein Fred H | Director | Jun 30 | Tender Offer · U | −577,316 | $2.20 | −$1.27M | 0 |
| Carr Daniel B | President and CMO | Jun 30 | Tender Offer · U | −80,494 | $2.20 | −$177K | 0 |
| Carr Daniel B | President and CMO | May 03 | Sale for tax withholding · S | −18,450 | $2.18 | −$40.2K | 137,518 |
| Tulipano Stephen J | CFO and Secretary | May 03 | Sale for tax withholding · S | −2,385 | $2.18 | −$5.2K | 22,615 |
| Carr Daniel B | President and CMO | Mar 26 | Open-market sale · S | −700 | $1.35 | −$945 | 155,968 |
| Carr Daniel B | President and CMO | Mar 26 | Exercise / conversion · M | +767 | $1.07 | +$821 | 156,668 |
| Carr Daniel B | President and CMO | Mar 25 | Open-market sale · S | −4,700 | $1.35 | −$6.35K | 155,901 |
| Carr Daniel B | President and CMO | Mar 25 | Exercise / conversion · M | +5,307 | $1.07 | +$5.68K | 160,601 |
| Driscoll Martin J | Chief Executive Officer | Mar 19 | Open-market buy · P | +22,181 | $1.30 | +$28.9K | 236,553 |
| Flanzraich Neil | Director | Mar 03 | Open-market buy · P | +84,580 | $1.41 | +$119K | 1,000,000 |
| Flanzraich Neil | Director | Feb 19 | Open-market buy · P | +100,000 | $1.42 | +$142K | 915,420 |
| Flanzraich Neil | Director | Feb 18 | Open-market buy · P | +11,000 | $1.42 | +$15.6K | 815,420 |
Loading...
